Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
OSE-2101 by OSE Immunotherapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
OSE-2101 is under clinical development by OSE Immunotherapeutics and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According...